Growth hormone releasing factor (GRF) increases free arachidonate levels in the pituitary: A role for lipoxygenase products

P. L. Canonico; C. Speciale; M. A. Sortino; M. J. Cronin; R. M. MacLeod; U. Scapagnini

doi:10.1016/0024-3205(86)90312-7

Growth hormone releasing factor (GRF) increases free arachidonate levels in the pituitary: A role for lipoxygenase products

P. L. Canonico, C. Speciale, M. A. Sortino, M. J. Cronin, R. M. MacLeod, U. Scapagnini

Research output: Contribution to journal › Article › peer-review

Abstract

GRF, a specific stimulator of GH release, increased in a concentration- and time-dependent manner pituitary [³H]- arachidonate levels in vitro. This effect was antagonized by 100 nM somatostatin. Exogenous arachidonate also stimulated GH release in vitro. Quinacrine, a phospholipase A2 inhibitor, reduced both basal and GRF-stimulated free arachidonate levels as well as GH release. The cyclooxygenase inhibitor indomethacin was ineffective, while BW755c, which also inhibits the lipoxygenase pathway, produced a further increase in the levels of the fatty acid stimulated by GRF and potently reduced GH release. These results provide additional evidence for the involvement of arachidonate metabolism in the hormone-releasing effect of GRF at the somatotroph.

Original language	English
Pages (from-to)	267-272
Number of pages	6
Journal	Life Sciences
Volume	38
Issue number	3
DOIs	https://doi.org/10.1016/0024-3205(86)90312-7
Publication status	Published - 20 Jan 1986
Externally published	Yes

Access to Document

10.1016/0024-3205(86)90312-7

Cite this

@article{a73b39e535004139b43ac5c37c8b26b9,

title = "Growth hormone releasing factor (GRF) increases free arachidonate levels in the pituitary: A role for lipoxygenase products",

abstract = "GRF, a specific stimulator of GH release, increased in a concentration- and time-dependent manner pituitary [3H]- arachidonate levels in vitro. This effect was antagonized by 100 nM somatostatin. Exogenous arachidonate also stimulated GH release in vitro. Quinacrine, a phospholipase A2 inhibitor, reduced both basal and GRF-stimulated free arachidonate levels as well as GH release. The cyclooxygenase inhibitor indomethacin was ineffective, while BW755c, which also inhibits the lipoxygenase pathway, produced a further increase in the levels of the fatty acid stimulated by GRF and potently reduced GH release. These results provide additional evidence for the involvement of arachidonate metabolism in the hormone-releasing effect of GRF at the somatotroph.",

author = "Canonico, {P. L.} and C. Speciale and Sortino, {M. A.} and Cronin, {M. J.} and MacLeod, {R. M.} and U. Scapagnini",

year = "1986",

month = jan,

day = "20",

doi = "10.1016/0024-3205(86)90312-7",

language = "English",

volume = "38",

pages = "267--272",

journal = "Life Sciences",

issn = "0024-3205",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - Growth hormone releasing factor (GRF) increases free arachidonate levels in the pituitary

T2 - A role for lipoxygenase products

AU - Canonico, P. L.

AU - Speciale, C.

AU - Sortino, M. A.

AU - Cronin, M. J.

AU - MacLeod, R. M.

AU - Scapagnini, U.

PY - 1986/1/20

Y1 - 1986/1/20

N2 - GRF, a specific stimulator of GH release, increased in a concentration- and time-dependent manner pituitary [3H]- arachidonate levels in vitro. This effect was antagonized by 100 nM somatostatin. Exogenous arachidonate also stimulated GH release in vitro. Quinacrine, a phospholipase A2 inhibitor, reduced both basal and GRF-stimulated free arachidonate levels as well as GH release. The cyclooxygenase inhibitor indomethacin was ineffective, while BW755c, which also inhibits the lipoxygenase pathway, produced a further increase in the levels of the fatty acid stimulated by GRF and potently reduced GH release. These results provide additional evidence for the involvement of arachidonate metabolism in the hormone-releasing effect of GRF at the somatotroph.

AB - GRF, a specific stimulator of GH release, increased in a concentration- and time-dependent manner pituitary [3H]- arachidonate levels in vitro. This effect was antagonized by 100 nM somatostatin. Exogenous arachidonate also stimulated GH release in vitro. Quinacrine, a phospholipase A2 inhibitor, reduced both basal and GRF-stimulated free arachidonate levels as well as GH release. The cyclooxygenase inhibitor indomethacin was ineffective, while BW755c, which also inhibits the lipoxygenase pathway, produced a further increase in the levels of the fatty acid stimulated by GRF and potently reduced GH release. These results provide additional evidence for the involvement of arachidonate metabolism in the hormone-releasing effect of GRF at the somatotroph.

UR - http://www.scopus.com/inward/record.url?scp=0022618154&partnerID=8YFLogxK

U2 - 10.1016/0024-3205(86)90312-7

DO - 10.1016/0024-3205(86)90312-7

M3 - Article

SN - 0024-3205

VL - 38

SP - 267

EP - 272

JO - Life Sciences

JF - Life Sciences

IS - 3

ER -

Growth hormone releasing factor (GRF) increases free arachidonate levels in the pituitary: A role for lipoxygenase products

Abstract

Access to Document

Other files and links

Fingerprint

Cite this